In a discovery that could fundamentally reshape the medical community’s approach to neurodegenerative disease, researchers at the University of Virginia School of Medicine have identified a specific immune system trigger that appears to drive the devastating cognitive decline associated with Alzheimer’s. The findings point to a single molecule, known as STING, as a primary culprit in the inflammatory process that ravages the brain, offering a promising new target for therapies that could potentially halt the progression of Alzheimer’s, Parkinson’s, and other memory-robbing conditions.
For decades, the search for an Alzheimer’s cure has largely focused on the accumulation of amyloid-beta plaques and tau protein tangles. However, the UVA team’s research suggests these hallmarks of the disease may be the end result of a deeper, more systemic failure: the immune system’s misguided attempts to repair DNA damage that naturally occurs as the brain ages. By identifying STING (Stimulator of Interferon Genes) as the bridge between cellular aging and brain inflammation, the researchers have uncovered what may be the "master switch" for the neuronal damage that defines neurodegeneration.
The study, led by John Lukens, PhD, and his team at UVA’s Harrison Family Translational Research Center in Alzheimer’s and Neurodegenerative Diseases, reveals that when this molecule becomes hyperactive, it transforms the brain’s internal defense system into a source of destruction. While the immune system is designed to protect the body from external threats like viruses, in the context of Alzheimer’s, it appears to turn inward, causing the very damage it is meant to prevent.
The Role of STING in the Aging Brain
The human brain is a highly metabolic organ, and over the course of a lifetime, its cells are subjected to constant wear and tear. This includes damage to the DNA within neurons. Under normal circumstances, the body has robust mechanisms to repair these genetic breaks or to safely clear out damaged cells. However, as the aging process accelerates, these repair mechanisms can falter, leaving behind fragments of damaged DNA.
This is where STING enters the picture. STING is an essential component of the innate immune system, acting as a high-alert sensor that detects the presence of DNA where it shouldn’t be—such as when a virus invades a cell or when a cell’s own genetic material leaks due to stress. When STING detects these "alarms," it triggers an inflammatory response intended to neutralize the threat.
The UVA research demonstrates that in the aging brain, the natural accumulation of DNA damage serves as a constant, false alarm for STING. This leads to a state of chronic, "wayward" inflammation. Instead of clearing out a temporary threat, the molecule drives a persistent immune response that inadvertently kills healthy neurons and fosters the environment necessary for plaques and tangles to form.
"Our findings demonstrate that the DNA damage that naturally accumulates during aging triggers STING-mediated brain inflammation and neuronal damage in Alzheimer’s disease," said Lukens. "These results help to explain why aging is associated with increased Alzheimer’s risk and uncover a novel pathway to target in the treatment of neurodegenerative diseases."
Alarming Trends in Alzheimer’s
The urgency of this research cannot be overstated. Alzheimer’s disease has become a looming public health crisis, not only in the United States but across the globe. Currently, more than 7 million Americans are living with the condition, a figure that places an immense emotional and financial burden on families and the healthcare system alike. Projections suggest that without a significant medical breakthrough, this number could skyrocket to 13 million by the year 2050.
Despite the billions of dollars invested in research over the last several decades, the underlying causes of Alzheimer’s have remained stubbornly murky. Early theories focused almost exclusively on the plaques themselves, but clinical trials targeting those plaques have often yielded disappointing results, failing to stop the cognitive slide even when the plaques were successfully cleared. This has led scientists to look for earlier triggers in the disease’s "cascade."
The UVA study adds to a growing body of evidence that the immune system—and specifically the brain’s resident immune cells, known as microglia—is the missing piece of the puzzle. When STING is activated, it directs these microglia to adopt a pro-inflammatory state. In their attempt to respond to the perceived threat of damaged DNA, these cells become hyperactive, damaging the very synapses and neurons they are supposed to support.
By focusing on STING, the UVA researchers are looking upstream of the plaques and tangles. They found that by blocking this molecule’s activity in laboratory mice, they could effectively "quiet" the immune response. This intervention not only prevented the formation of amyloid plaques but also altered the activity of microglia in a way that protected the brain’s architecture and preserved memory function.
"We found that removing STING dampened microglial activation around amyloid plaques, protected nearby neurons from damage and improved memory function in Alzheimer’s model mice," explained Jessica Thanos, a researcher in UVA’s Department of Neuroscience and the Center for Brain Immunology and Glia (BIG Center). "Together, these findings suggest that STING drives detrimental immune responses in the brain that exacerbate neuronal damage and contribute to cognitive decline in Alzheimer’s disease."
Promising Treatment Target
One of the most significant aspects of this discovery is that STING appears to be a "dual-threat" target. In the complex landscape of Alzheimer’s pathology, there are two primary villains: amyloid-beta plaques and tau tangles. Most experimental drugs target one or the other, often with limited success because the two processes are deeply intertwined.
The UVA Health researchers found that STING is uniquely positioned because it appears to influence both. Blocking the molecule slowed the buildup of plaques while simultaneously hindering the development of tau tangles. This robust involvement makes STING a much more attractive target than other molecules that may only be relevant during very specific, narrow windows of the disease’s progression.
Furthermore, the implications of this discovery extend far beyond Alzheimer’s. Because STING responds to the fundamental biological process of DNA damage and inflammation, it is likely a key contributor to a spectrum of neurodegenerative conditions. The researchers believe that therapies targeting STING could eventually be used to treat Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and various forms of dementia.
"We are only beginning to understand the complex role of innate immune activation in the brain, and this is especially true in both normal and pathological aging," Thanos said. "If we can pinpoint which cells and signals sustain that activation, we will be in a much better position to intervene effectively in disease."
The Path to Translation
While the results in laboratory models are groundbreaking, the transition from mouse studies to human treatments is a rigorous and lengthy process. The UVA team is now focused on the next steps of translational research—the process of turning laboratory discoveries into "bedside" medicine for patients.
One of the primary challenges will be ensuring that any treatment designed to block STING is safe for human use. Because STING plays a vital role in the body’s ability to fight off viruses and potentially even recognize and destroy cancer cells, scientists must find a way to dampen its harmful effects in the brain without compromising the rest of the immune system. A delicate balance must be struck to ensure that a treatment for Alzheimer’s doesn’t inadvertently leave a patient vulnerable to other diseases.
These are the questions that Lukens and his colleagues at the Harrison Family Translational Research Center are prepared to investigate. The center is a vital part of UVA’s Paul and Diane Manning Institute of Biotechnology, a massive research hub currently under construction at Fontaine Research Park. The institute is designed to accelerate the development of next-generation treatments, including cellular and gene therapies, and the STING research is expected to be a cornerstone of its neurodegeneration portfolio.
"Our hope is that this work moves us close to finding safer and more effective ways to protect the aging brain, as there is an urgent need for treatments that can slow or prevent neuronal damage in Alzheimer’s," Lukens said. "Shedding light on how STING contributes to that damage may help us target similar molecules and ultimately develop effective disease-modifying treatments."
Findings Published
The full scope of the study and its findings have been published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, the field’s premier peer-reviewed journal. The multidisciplinary research team included Thanos, Olivia C. Campbell, Maureen N. Cowan, Katherine R. Bruch, Katelyn A. Moore, Hannah E. Ennerfelt, Nick R. Natale, Aman Mangalmurti, and Nagaraj Kerur, alongside Lukens.
The researchers reported no financial conflicts of interest in the work, which was made possible through extensive support from the National Institutes of Health’s National Institute of Aging. Additional funding was provided by the Alzheimer’s Association, the Cure Alzheimer’s Fund, the Owens Family Foundation, and the Harrison Family Foundation.
As the global population continues to age, the race to solve the mystery of Alzheimer’s has never been more critical. By identifying STING as a driver of the disease, the University of Virginia has provided a new roadmap for scientists, offering hope to millions that a future without the shadow of neurodegeneration may finally be within reach.
